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Hyperphosphatemia is a driving force in the pathogenesis of
vascular calcification (VC) and secondary
hyperparathyroidism associated with renal failure. To test for
the possible contribution of parathyroid hormone (PTH) to
cardiovascular calcification, we removed the parathyroid
glands from rats but infused synthetic hormone at a
supraphysiologic rate. All rats were pair-fed low, normal, or
high phosphorus diets and subjected to a sham or 5/6
nephrectomy (remnant kidney). Control rats were given a
normal diet and underwent both sham parathyroidectomy
and 5/6 nephrectomy. Heart weight/body weight ratios and
serum creatinine levels were higher in remnant kidney rats
than in the sham-operated rats. Remnant kidney rats on the
high phosphorus diet and PTH replacement developed
hyperphosphatemia and hypocalcemia along with low bone
trabecular volume. Remnant kidney rats on the low
phosphorus diet or intact kidney rats on a normal
phosphorus diet, each with hormone replacement,
developed hypercalcemia. All rats on PTH replacement
developed intense aortic medial calcification, and some
animals presented coronary calcification. We suggest that
high PTH levels induce high bone turnover and medial
calcification resembling Mo¨mckeberg’s sclerosis independent
of uremia. This model may be useful in defining mechanisms
underlying VC.
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Cardiovascular diseases are the leading causes of death in
patients with chronic kidney disease (CKD) and account for
at least 50% of deaths in this population,1 especially among
those undergoing dialysis.2,3 Although there is undoubtedly
an excess of cardiovascular mortality, the factors involved
have not been conclusively identified. One likely factor is
vascular calcification (VC). In CKD patients, histologic and
radiographic evidences of VC are markedly higher than in the
general population4 and has been shown to have a significant
adverse influence on a number of surrogate markers for
cardiovascular disease mortality. Several explanations for this
striking degree of VC observed in CKD patients have been
proposed, including deregulation of the calcium/phosphate
metabolism implicit in renal osteodystrophy and the
influence of CKD treatment with calcium-containing phos-
phate binders or vitamin D analogs.4
The importance of managing hyperphosphatemia has
classically been emphasized because of its role in the
pathogenes of secondary hyperparathyroidism.5 However,
disturbances in phosphorus metabolism and parathyroid
hormone (PTH) have other significant adverse conse-
quences.6 In recent studies, hyperphosphatemia, alone or in
combination with the measures currently used to control it,
has been implicated in the substantially higher incidence of
cardiovascular mortality, as well as in the higher incidence of
visceral and peripheral VC, seen in patients with advanced
CKD.7 Although the exact mechanism is unknown, VC may
be involved. Jono et al.8 showed, in vitro, that inorganic
phosphate transformed vascular smooth muscle cells into
calcifying cells by a direct mechanism involving the
phosphate cotransporter Pit-1. Hyperphosphatemia-related
hypersecretion of PTH may also be indirectly involved.9 As
for the exact effects that PTH has on VC, this is still a matter
of debate. Recently, high PTH serum levels were associated
with higher mortality rates in dialysis patients.6,10 However,
there have been some in vitro studies in which a direct effect
of PTH on VC could not be confirmed11 and others in which
it was argued that PTH treatment of osteoporosis can also
decrease VC progression.12 Finally, an isolated PTH or
phosphorus effect cannot be evaluated in CKD patients
because hyperphosphatemia is typically accompanied by
elevated PTH and other factors that could interfere with
their effects. In addition, many patients receive treatment for
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hyperphosphatemia or hyperparathyroidism that could itself
facilitate VC, worsen renal function, and adversely affect bone
remodeling. Using an experimental model of chronic renal
failure with continuous infusion of a physiological concen-
tration of PTH, we recently demonstrated that isolated
hyperphosphatemia was accompanied by myocardial hyper-
trophy, worsening of renal function, and negative effects on
bone remodeling.13 However, in that study, we observed no
VC, even in the presence of severe hyperphosphatemia.
In this study, we designed an experimental model
involving diets with high phosphorus content that would
induce hyperphosphatemia or low phosphorus content to
control phosphorus levels, as well as measures to ensure
constant, high levels of PTH.14 We did so to investigate the
isolated effect of PTH on cardiovascular calcification, cardiac
fibrosis, other cardiovascular changes, renal function, and
bone, in animals with chronic experimental uremia as well as
in those with normal renal function.
RESULTS
Body weight, food intake, tail cuff plethysmography, and
heart weight/body weight ratio
Table 1 and Figure 1 summarize the animal data. The
duration of the uremia and diet-treatment experiments was
52 days. Initial body weight did not differ among the groups.
Despite the pair-feeding protocol, LPþ hi-PTHþNx rats
had the lowest final body weights. All Nx rats presented
slightly lower food intake than did those with normal renal
function. Initial tail cuff plethysmography readings were
similar among all groups. After 8 weeks of uremia, all Nx rats
developed hypertension, as did CPþ hi-PTH rats. Regarding
the heart weight/body weight ratio (HW/BW), Nx animals
developed myocardial hypertrophy.
Biochemical findings
In Table 2, Figures 1 and 2, biochemical findings from all
animals.
Hematocrit levels were higher in CPþ SHAM rats. The Nx
rats presented higher serum magnesium levels, although the
difference was only statistically significant for LPþ
hi-PTHþNx rats. The Nx rats developed moderate renal
failure and proteinuria. The HPþ hi-PTH rats presented
lower creatinine clearance than their corresponding controls
(CPþ hi-PTH) and CPþ SHAM rats. Reposition of PTH
was similar among all hi-PTH groups. The HPþ hi-
PTHþNx rats presented very low iCa levels and developed
pronounced hyperphosphatemia, as evidenced by a marked
elevation in calcium phosphorus (Ca P) product – even
in the presence of hypocalcemia. The LPþ hi-PTHþNx and
the CPþ hi-PTH rats developed significant hypercalcemia.
However, there were no differences in Ca P product among
the hi-PTH groups.
Morphological results
Tables 3 and 4 and Figure 1 show the results of the bone
histomorphometric analysis. All hi-PTH rats developed
features of hyperparathyroidism bone disease, presenting
higher bone formation and resorption accompanied by
medullar fibrosis. Trabecular volume and osteoid surface
area were greater in LPþ hi-PTHþNx rats than in HPþ hi-
PTHþNx rats. Trabecular separation was higher in the
HPþ hi-PTHþNx animals than in their LPþ hi-PTHþNx
counterparts, denoting an osteoporotic effect of the HP diet
in uremic rats. Although the differences were not statistically
significant, HPþ hi-PTH and CPþ hi-PTH rats presented
higher bone formation rate/bone surface and lower minera-
lization lag time than did Nx rats.
Qualitative analysis of myocardial, renal, and arterial
histology revealed that all hi-PTH rats developed intense
aortic medial calcification. Macroscopically, the aortic artery
had a ‘tram-line’ appearance resembling Mo¨nckeberg’s
sclerosis. The diffuse mineral deposition occurred in the
internal elastic lamina, particularly surrounding fractured
disorganized elastin fibers. The medial vascular smooth
muscle cells acquired cuboid aspects. The VC pattern was
comparable among all hi-PTH groups. No intimal calcifica-
tion was seen (Figure 3). Some animals also presented
coronary medial calcification, and one rat in the HPþ hi-
PTHþNx group also presented medial arterial calcification
in the renal artery. Sparse calcium deposits in myocardial and
kidney tissue were detected in some hi-PTH rats. Perivascular
fibrosis was seen in the myocardial tissue of hi-PTH rats
(Figure 4).
DISCUSSION
This study showed that rats receiving continuous infusion of
high concentrations of PTH develop massive aortic medial
calcification resembling Mo¨nckeberg’s sclerosis, as well as
coronary medial calcification. These findings were apparently
unrelated to the differences in dietary phosphorus or the
Table 1 | Animal data
Initial BW (g) Final BW (g) Food intake (g/day)
HP+hi-PTH+Nx (n=7) 336.478.5 340.1720.8 11.970.9b
LP+hi-PTH+Nx (n=9) 316.073.2 305.977.3a 12.370.29b
HP+hi-PTH (n=6) 342.776.4 385.3715.5 16.070.65
CP+hi-PTH (n=5) 350.575.5 410.678.9 16.370.42
CP+SHAM (n=10) 328.776.2 377.6713.2 15.670.33
BW, body weight; CP, control phosphorus diet; hi-PTH, high PTH; HP, high phosphorus diet; LP, low phosphorus diet; Nx, nephrectomized rat; PTH, parathyroid hormone;
SHAM, sham-operated.
aPo0.05 vs all; bPo0.05 vs Non-Nx rats.
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presence or absence of renal insufficiency. These conditions
were observed in animals with severe hypocalcemia and
hyperphosphatemia (HPþ hi-PTHþNx), in animals with
hypercalcemia and normal phosphorus levels (LPþ hi-
PTHþNx and CPþ hi-PTH) and in animals with normal
levels of calcium and phosphorus (HPþ hi-PTH). This effect
was not related to a decrease in serum magnesium levels. In
addition, high infusion of PTH was correlated with
development of myocardial hypertrophy in Nx groups.
Another important and original finding was the skeletal
resistance to PTH resulting from hyperphosphatemia sec-
ondary to phosphorus overload in uremic rats.
In our study, we demonstrated the relationship between
high PTH levels and VC previously described in dialysis
patients.3,15 We also showed that high PTH levels caused
VC even in the presence of low calcium or normal
phosphorus levels or preserved renal function. There have
been very few in vivo experimental studies evaluating VC in
a uremic milieu. Recently, Tamagaki et al.16 and de Graaf
et al. (abstract presented at ASN Renal Week, 2005) devised
an experimental model of VC in uremic adenine-treated rats.
In both models, serum levels of PTH were extremely high
(more than six times than those achieved in our model), and
the authors also observed massive VC. However, it is not
possible to conclude that this was related solely to the effects
of PTH and not also to those of hyperphosphatemia and of
the higher calcium content in their diets. In our model,
we demonstrated that continuous high PTH levels per se
were capable of inducing VC development in rats, although
we were unable to determine whether this was a direct or
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Figure 1 | Biochemical and histomorphometric data. (a) HW/BW was significantly higher in Nx animals. (b) Animals submitted to
nephrectomy and from CPþ hi-PTH had higher tail cuff plethysmography pressure than did HPþ hi-PTH and CPþ SHAM animals. (c) Animals
submitted to nephrectomy had a lower creatinine clearance (CrCl) levels than non-Nx animals. Non-Nx rats that were submitted to high
phosphorus diet and to high PTH infusion (HPþ hi-PTH) presented lower CrCl than did their CPþ hi-PTH counterparts and CPþ SHAM rats.
(d) The anabolic effect of PTH was marked in Nx rats fed a low phosphorus diet (LPþ hi-PTHþNx rats) but was partially blunted in Nx rats
fed a high phosphorus diet (HPþ hi-PTHþNx rats), indicating skeletal resistance to PTH. *Po0.05 vs Non-Nx animals; þPo0.05 vs HPþ hi-PTH
and CPþ SHAM;  Po0.05 vs CPþ SHAM and CPþ hiPTH; fPo0.05 vs LPþ hi-PTHþNx.
Table 2 | Biochemical data
Ht (%) Mg (mg/dl) UProt (g/24 h) Cr (mg/dl) CrCl (ml/min)
HP+hi-PTH+Nx (n=7) 36.770.9 2.171.2 4.270.5b 1.070.15b 0.570.1b
LP+hi-PTH+Nx (n=9) 39.471.6 2.570.1b 2.670.7b 1.070.10b 0.670.1b
HP+hi-PTH (n=6) 38.570.6 1.570.1 0.970.2 0.570.04 1.370.1c
CP+hi-PTH (n=5) 38.272.1 1.970.1 0.670.1 0.370.10 2.570.4
CP+SHAM (n=10) 46.370.9a 1.970.2 0.770.1 0.470.02 2.170.2
Cr, creatinine; CrCl, creatinine clearance; hi-PTH, high PTH; HP, high phosphorus diet; Ht, hematocrit; LP, low phosphorus diet; Mg, magnesium; Nx, nephrectomized rat;
P, phosphorus; PTH, parathyroid hormone; SHAM, sham-operated; UProt, proteinuria.
aPo0.05 vs all; bPo0.05 vs non-Nx rats; cPo0.05 vs CP+hi-PTH and CP+SHAM.
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indirect effect. In addition, as we demonstrated previously,13
VC is not observed in the presence of hyperphosphatemia
and physiological continuous PTH reposition. The VC
described in our animals could be related to a direct effect
of PTH on vascular smooth muscle cells. PTH administration
has the theoretical potential to augment mineral deposition
and turnover via its anabolic effects. However, Jono et al.17
and Shao et al.,12 using experimental models not involving
renal failure, found that pharmacological administration of
PTH (1–34) prevented and regulated osteogenic VC. It was
also demonstrated that stimulation of PTH1R with this PTH
fragment inhibited calcification by bovine vascular smooth
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Figure 2 | Biochemical data. (a) Rats that received a hi-PTH (hi-PTH) infusion presented higher PTH (PTH) levels than did sham-operated
(CPþ SHAM) animals. (b) Nx-hi-PTH animals fed a high phosphorus diet (HPþ hi-PTHþNx rats) presented very low ionized calcium (iCa) levels,
whereas those fed a low phosphorus diet (LPþ hi-PTHþNx rats) developed significant hypercalcemia, as well as CPþ hi-PTH rats. (c) HPþ
hi-PTHþNx animals presented intense hyperphosphatemia. (d) Calcium vs phosphorus product (Ca P) was significantly higher in all hi-PTH
rats. aPo0.05 vs all; þPo0.05 vs HPþ hi-PTH and CPþ SHAM.
Table 3 | Static histomorphometric variables of trabecular bone in the distal femur
BV/TV
(%)
OV/BV
(%)
O.Th
(l)
OS/BS
(%)
ES/BS
(%)
Ob.S/BS
(%)
Oc.S/BS
(%)
Fb.V
(%)
Tb.Sp
(l/m)
Tb.N
(/mm)
Tb.Th
(l/m)
HP+hi-PTH+Nx (n=7) 25.672.2 3.571.1 2.770.4 32.074.7 25.874.3 27.575.0 6.270.8 1.470.6 177.2712.9 4.370.2 59.974.1
LP+hi-PTH+Nx (n=9) 39.373.3b 4.870.6 3.470.3 44.772.1b 25.071.9 37.071.8 7.870.7 2.470.8 111.9715.0b 6.170.6b 66.273.0
HP+hi-PTH (n=6) 37.674.6 4.470.6 3.270.3 47.173.2 20.472.6 40.272.8 6.771.1 1.570.6 124.9717.3 5.270.4 70.975.4
CP+hi-PTH (n=5) 29.975.7 5.171.0 3.670.5 45.874.6 25.871.9 37.673.7 8.971.5 1.270.9 174.0731.6 4.570.7 65.474.1
CP+SHAM (n=10) 23.471.7c 0.270.1a 1.670.2a 3.770.6a 8.271.5a 2.170.4a 2.170.7a 0 229.0721.0c 3.570.2b,c 66.671.6
BV/TV, trabecular bone volume/total volume; CP, control phosphorus diet; ES/BS, eroded surface/bone surface; Ob.S/BS, osteoblast surface/bone surface; Fb.V, fibrosis
volume; hi-PTH, high PTH; HP, high phosphorus diet; LP, low phosphorus diet; Nx, nephrectomized rat; O.Th, osteoid thickness; Oc.S/BS, osteoclast surface/bone surface;
OS/BS, osteoid surface/bone surface; OV/BV, osteoid volume/bone volume; SHAM, sham-operated; Tb.N, trabecular number; Tb.Sp, trabecular separation; Tb.Th,
trabecular thickness.
aPo0.05 vs all; bPo0.05 vs HP+hi-PTH+Nx; cPo0.05 vs HP+hi-PTH and LP+hi-PTH+Nx.
Table 4 | Dynamic histomorphometric variables of trabecular bone in the distal femur
MAR (l/day) MS/BS (%) BFR/BS (l3/l2/day) MLT (day)
HP+hi-PTH+Nx (n=7) 1.270.3 4.170.9 0.0470.01 41.9719.5
LP+hi-PTH+Nx (n=9) 0.770.2 3.170.7 0.0470.01 88.2725.5a
HP+hi-PTH (n=6) 0.870.1 8.570.9c 0.0970.02 26.274.6
CP+hi-PTH (n=5) 0.870.1 9.271.2c 0.0770.01c 26.876.1
CP+SHAM (n=10) 0.770.1 3.370.4 0.0270.0 2.770.5a,b
BFR/BS, bone formation rate/bone surface; CP, control phosphorus diet; hi-PTH, high PTH; HP, high phosphorus diet; HP, high phosphorus diet; LP, low phosphorus diet;
MAR, mineral apposition rate; MLT, mineralization lag time; MS/BS, mineralization surface/bone surface; Nx, nephrectomized rat; PTH, parathyroid hormone; SHAM, sham-
operated.
aPo0.05 vs non-Nx rats; bPo0.05 vs HP+hi-PTH and LP+hi-PTH+Nx; cPo0.05 vs Nx rats and CP+SHAM.
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muscle cells. The authors administered PTH intermittently,
whereas we used continuous infusion of PTH at high flow
rates. It has been shown that continuous administration of
PTH in animals with normal renal function decreases bone
mass and intermittent PTH has an anabolic effect on bone.18
Although as yet unevaluated in vessels, this continuous vs
intermittent infusion difference could explain our findings.
Another possibility is that, in this model, PTH could exert an
indirect effect, increasing calcium load (in LPþ hi-PTHþNx
and CPþ hi-PTH rats) or phosphorus load (in HPþ hi-
PTHþNx and HPþ hi-PTH rats). Some in vitro studies
have suggested that calcium and phosphorus induce VC
independently and synergistically.19 Therefore, continuous
infusion of PTH at high flow rates could very well lead to
massive VC such as that observed in our model. This
probably occurred because, in the model presented herein,
PTH is no longer regulated, because it is administered
exogenously (but retains its function in elevating calcium
levels), whereas in other models elevated PTH levels are the
result of changes in calcium and phosphorus metabolism.
Another question that arises is why massive VC was observed
in animals with PTH levels that were lower than those
observed by other authors.16 One possibility is that the assay
employed in our experiment could result in an under-
estimation of the PTH values. However, it was a two-site
immunoradiometric assay with two different antibodies to
the N-terminal region (1–34) of rat PTH. As our animals
were parathyroidectomized before the miniosmotic pump
implantation, and all the circulating PTH was N terminal, it
seems that this assay truly measured all of the PTH values
delivered. Nevertheless, we cannot rule out the possibility
that, in the studies conducted by other authors, some of the
PTH values measured were not intact, and that, in fact, the
PTH values were overestimated for these animals. We could
also hypothesize that the continuous PTH infusion used in
our model mobilizes calcium and phosphorus from the bone
more efficiently than does the endogenous PTH increase seen
in the other models. Consequently, even with lower PTH
levels, calcium, and phosphorus fluxes from the bone in our
model were similar to those observed in the Tamagaki et al.16
study. Another possibility is that the continuous PTH
infusion could lead to a decrease in VC inhibitors, such as
pyrophosphate or matrix gla protein (MGP). Murshed
et al.,20 in a very elegant study, analyzed the effect of a high
phosphate diet in normal and genetically modified non-
uremic mice. The authors showed that hyperphosphatemia
alone did not induce VC in the wild-type mice. However,
animals that are genetically deficient in MGP (MGP/) or
pyrophosphate (ank) presented VC or joint calcification,
respectively, even in the presence of normal serum phosphate
levels. When MGP/ and ank mice were placed on a Hyp
genetic background (hypophosphatemic mice), the ectopic
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Figure 3 | Massive medial aortic calcification observed in hi-PTH rats. (c and d) HPþ hi-PTHþNx; (e and f) LPþ hi-PTHþNx;
(g and h) HPþ hi-PTH; (i and j) CPþ hi-PTH compared with sham rats; (a and b) CPþ SHAM. We observed a morphological change in cells
from the medial layer, suggesting a phenotypic change. Original magnification (a, c, e, g, and i),  100; (b, d, f, h, and j),  400.
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extracellular mineralization disappeared. Finally, the MGP/;
Hyp and ank;Hyp mice recuperated their ectopic extracellular
mineralization phenotype when they were fed with a high
phosphate diet. Unfortunately, it was not possible to measure
MGP, pyrophosphate, or serum vitamin D levels in our
experiment.
Another significant finding was myocardial hypertrophy,
as suggested by the higher HW/BW ratio and perivascular
fibrosis seen in hi-PTH uremic rats. Cardiovascular cells
(cardiomyocytes and smooth muscle cells) are targets for
PTH, which activates protein kinase C of cardiomyocytes and
leads to hypertrophic growth and reexpression of fetal-type
proteins.21 This might explain the myocardial hypertrophy
observed. In addition, PTH has been characterized as a
permissive factor in the development of interstitial fibrosis in
myocardial tissue.22 Nevertheless, arterial hypertension,
uremia, and anemia, as well as arterial stiffening due to
VC, might also be associated with myocardial hypertrophy in
our animals.
Many factors that may influence the progression of renal
failure have been identified. Predominant among these are
glomerular factors, hemodynamic factors, systemic hyperten-
sion, and hyperparathyroidism, as well as high dietary levels
of protein and phosphorus.23 We recently demonstrated
that isolated hyperphosphatemia is correlated with progres-
sive renal failure, and that restricting dietary phosphorus
(even at constant normal PTH levels) protects renal
function.13 In the present study, we again demonstrated that
phosphorus overload, even in the absence of an initial renal
injury (Nx) and in the presence of high PTH levels,
accelerates the progression of renal dysfunction, because
our HPþ hiPTH rats presented lower creatinine clearance
than did the other non-Nx animals. It is assumed that
calcium phosphate deposition resulting from hyperphos-
phatemia and elevated PTH levels incites tissue injury.
Cozzolino et al.24 analyzed the impact of various phosphate
binders on kidney tissue.The authors found higher calcium
deposition in the kidneys of untreated rats (with high levels
of phosphorus and PTH), as well as in those of calcium salt-
treated rats (with control of phosphorus and PTH levels, but
with a high calcium load). However, in our study, the
worsening of renal function was apparently unrelated to
nephrocalcinosis, because we found only sparse calcification
in hi-PTH animals.
We found that infusion of PTH above the physiological
range induced some skeletal PTH-related changes. In hi-PTH
rats, we noted higher bone resorption and development of
medullary fibrosis, as well as greater osteoblast and osteoclast
surface area. However, HPþ hi-PTHþNx rats presented an
attenuated response to PTH infusion, indicating skeletal
resistance to PTH in the presence of uremia. In HPþ
hi-PTHþNx rats, we found lower trabecular bone volume,
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Figure 4 | Coronary arteries from hi-PTH rats. (c and d) HPþ hi-PTHþNx; (e and f) LPþ hi-PTHþNx; (g and h) HPþ hi-PTH;
(i and j) CPþ hi-PTH; (a and b) disclosed medial calcification, whereas those in the CPþ SHAM group did not. Original magnification
(a, c, e, g, and i),  100; (b, d, f, h, and j),  400.
Kidney International (2007) 71, 1262–1270 1267
KR Neves et al.: Vascular calcification in experimental renal failure o r i g i n a l a r t i c l e
together with a significant loss of connectivity. This
phosphorus-osteoporotic effect was not found in non-Nx
rats, suggesting that, at least in our model, normal renal
function and hyperparathyroidism prevent this phosphorus-
induced osteopenia. It has long been known that CKD
patients present resistance to the effect of PTH.25 Histomor-
phometric studies of human bone biopsies in uremic patients
have shown that intact PTH levels several times greater than
normal are required to maintain bone turnover parameters
within normal ranges.26 However, the mechanisms involved
in skeletal resistance to PTH in renal failure remain unclear.
It is well accepted that high PTH levels result in homologous
desensitization and downregulation of the PTH1R/adenylate
cyclase system. Several lines of evidence indicate that, in the
uremic environment, there are additional circulating factors
that contribute to decreasing PTH1R expression.27 Some in
vivo studies of animals with renal failure have implicated
hyperphosphatemia as an important factor in the develop-
ment of PTH resistance.28 Meleti et al.29 performed an
experimental study in which the viability of osteoblast-like
cells in culture media was evaluated at increasing concentra-
tions of inorganic phosphate. The authors noted that the
phosphate-treated cells presented increased apoptosis and
displayed a profound loss of mitochondrial membrane
potential, suggesting that the anion activated cell death
through the induction of a mitochondrial membrane
permeability transition. This leads us to speculate that, in
our model, the rate of osteoblast apoptosis (as evidenced by
lower osteoblast surface/bone surface) was higher in uremic
animals that were fed a high phosphorus diet that leaded to a
decreased bone trabecular volume.
In conclusion, we have developed a new animal model of
VC, characterized by medial calcification, especially in aortic
and coronary arteries, and accompanied by the development
of PTH-related bone lesions. These vascular and bone
findings are similar to those commonly seen in CKD patients
on dialysis. As previously mentioned, this study had various
limitations (absence of serum vitamin D values, possible
differences in continuous vs intermittent PTH infusion and
the as yet unanswered question of whether it is the PTH itself
or an indirect mechanism that leads to VC). Nevertheless, we
believe that this model could be useful in studying the
mechanisms that underlie VC, as well as the skeletal
resistance to PTH found in uremia, because it is easily
reproducible, and it mimics many of the features found in
CKD. In addition, our findings underscore the importance of
PTH and phosphorus control in reducing the morbidity and
mortality described in CKD patients. The molecular basis of
the effect of PTH and hyperphosphatemia on target organs
should be elucidated in further studies.
MATERIALS AND METHODS
Experimental protocol
A total of 37 male Wistar rats, at initial weights of 300–400 g,
were obtained from our local breeding colony for use in this 9-week
study. All were housed in individual cages in a light-controlled
(12 h-on/12 h-off) environment in which temperature (251C) and
humidity (25%) were constant. The rats were anesthetized with
pentobarbital (50 mg/kg intraperitoneally) and divided into five
groups. Animals in Group 1 (n¼ 7), Group 2 (n¼ 9), Group 3
(n¼ 6), and Group 4 (n¼ 5) were then submitted to parathyr-
oidectomy, involving microsurgical techniques using electrocautery,
whereas those in Group 5 (n¼ 10) were submitted
to a sham version of the same procedure. The animals were allowed
a 1-week recovery period, after which they were anesthetized as
before, and a second operation was performed. Group 1 and
2 rats presenting ionized calcium (iCa) levels o0.9 mmol/l were
submitted to 5/6 nephrectomy (Nx), which consists of removal of
the right kidney and infarction of approximately two-thirds of
the left kidney. Group 3 and 4 rats presenting ionized calcium
(iCa) levels o0.9 mmol/l were submitted to sham Nx. Group 5
(SHAM control) rats underwent a second sham operation.
Simultaneous to the Nx and the sham Nx procedures, an Alzet
model 2ML4 osmotic minipump (Alza Corp., Palo Alto, CA, USA)
was implanted subcutaneously in each rat. In Group 1–4 rats, PTH
activity was restored by continuous infusion of 1–34 rat PTH
(Sigma-Aldrich, St Louis, MO, USA) at a supraphysiological
infusion rate (0.11mg/100 g/h),11 five times higher than that used
to reestablish normocalcemia in parathyroidectomized rats. Rats in
those four groups were designated hi-PTH rats. In the sham controls
(SHAM), the minipumps were used to deliver vehicle only (2%
cysteine; Sigma-Aldrich). Before the surgical procedures, all animals
had been fed identical diets of rodent chow (Harlan-Teklad,
Indianapolis, IN, USA). Immediately after the second procedure,
phosphorus content was altered in the diets of the study animals.
Group 5 rats continued to receive the same control (normal)
phosphorus diet (CP¼ 0.7% phosphorus) and were designated
CPþ SHAM rats. Group 1 rats received a high phosphorus
(HP, 1.2%) diet and were designated HPþ hi-PTHþNx rats. Rats
in Group 2 received a low phosphorus (LP, 0.2%) diet and
were designated LPþ hi-PTHþNx rats. Group 3 rats received a
HP diet and were designated HPþ hi-PTH rats, whereas Group 4
rats received a CP diet and were designated CPþ hi-PTH rats.
All diets were equal in caloric content, as well as in quantity of
vitamin D, calcium (0.7%), protein (24%), and calories. A pair-
feeding protocol was used, that is sham Nx rats received the same
amount of food that was consumed by the Nx rats the day before.
Weight measurement and tail cuff plethysmography were performed
weekly. On post-Nx day 28, all animals were given light ether
anesthesia and the osmotic minipump was replaced (pumping
lifetime of 28 days) with another minipump set to the same infusion
rate. A fluorochrome bone marker (oxytetracycline) in a dose of
25 mg/kg was intraperitoneally injected on days 11 and 12, as well as
on days 4 and 5 before killing. For the last 2 days of the 8-week
study, the rats were held in metabolic cages, and 24-h urine samples
were collected for biochemical analysis. On post-Nx day 52, the
animals were anesthetized and killed through aortic puncture
exsanguination. Serum samples were frozen at 201C for later
biochemical evaluation. Whole blood was also collected to
determine hematocrit levels. Hearts were excised, blotted, and
weighed. We also determined the heart weight to 100 g of body
weight ratio (HW/BW). The thoracic aorta was carefully removed
and fixed in buffered formalin, together with the heart and left
kidney.
All experimental procedures were conducted in accordance with
the guidelines of the Standing Committee on Animal Research of the
University of Sa˜o Paulo (CAPPesq number 293/01).
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Analytical determination
On the day of Nx surgery, whole blood had been collected by retro-
orbital puncture. A model AVL-9140 autoanalyzer (AVL Scientific
Corporation, Roswell, GA, USA) was used to measure iCa levels in
this blood, either immediately after collection or after killing (in
frozen samples). Serum creatinine and urinary creatinine were
determined using a colorimetric assay (modified Heinegard–Tider-
stro¨m). Phosphorus was also determined using a colorimetric assay
(Labtest, Lagoa Santa, Brazil). Magnesium was determined using a
diagnostic kit (Labtest, Sa˜o Paulo, Brazil). An immunoradiometric
assay (IRMA kit; Immutopics, San Clemente, CA, USA) was used to
measure rat PTH. Hematocrit was also determined. Proteinuria
(UProt) was measured using turbidimetry (sulfosalicylic acid).
Creatinine clearance (CrCl) was calculated using the following
standard formula:
CrCl ¼ UCrðmg=dlÞVuðml=24hÞ=½1440 minSCrðmg=dlÞ
where CrCl is creatinine clearance, UCr is urinary creatinine, Vu is
urinary volume, and SCr is serum creatinine.
Morphological techniques
Bone histomorphometry. At the study end point (killing), the
left femur of each rat was removed, dissected free of soft tissue,
immersed in 70% ethanol, and processed as described previously.30
Using a Jung K microtome (Reichert-Jung, Heidelberg, Germany),
distal femurs were cut into 5- and 10-mm-thick sections. The 5-mm
sections were stained with 0.1% toluidine blue (pH 6.4), and at least
two nonconsecutive sections were examined per sample. Static,
structural, and dynamic parameters of bone formation and
resorption were measured at the distal metaphyses (original
magnification,  250; 30 fields), 195mm from the epiphyseal growth
plate, using an Osteomeasure image analyzer (Osteometrics, Atlanta,
GA, USA). Mineral apposition rate (mm/day) was determined by
dividing the distance between the two oxytetracycline labels by the
time interval between the two oxytetracycline administrations.
Mineralization lag time is expressed in days. Determining double-
oxytetracycline-labeled (mineralizing) surface per bone surface and
bone formation rate completed the dynamic evaluation. Static
histomorphometric indices included trabecular bone volume/total
volume ratio, fibrosis volume, and osteoid volume/bone volume
ratio (all expressed as percentages), as well as osteoid thickness (in
mm). The percentage of total trabecular surface is used to express
areas of eroded, osteoid, osteoblast, and osteoclast surfaces.
Trabecular thickness and trabecular separation are expressed in
micrometers. Trabecular number is expressed per millimeter.
Histomorphometric indices are reported using nomenclature
recommended by the American Society of Bone and Mineral
Research.31 All animal data were obtained in a blinded fashion.
Cardiovascular histology. Cross-sections of the heart, thoracic
aorta, and left kidney were embedded in paraffin and cut into 4-mm
sections, which were then stained with periodic acid-Schiff, Masson
trichrome, and von Kossa stains. A pathologist blinded to the origins
of the samples performed a qualitative analysis of calcification and
fibrosis.
Statistical analysis
Statistical analysis was performed using the Student’s t-test.
Comparisons among the groups were made using one-way ANOVA
and Tukey’s post hoc test. GraphPad Prism software, version 4.0
(GraphPad, San Diego, CA, USA) was used. Results are presented
as mean7SE. Values of Po0.05 were considered statistically
significant.
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